A Review of Subthreshold Micropulse Laser and Recent Advances in Retinal Laser Technology by Daniel Su & Jean-Pierre Hubschman
REVIEW
A Review of Subthreshold Micropulse Laser and Recent
Advances in Retinal Laser Technology
Daniel Su . Jean-Pierre Hubschman
Received: December 18, 2016
 The Author(s) 2017. This article is published with open access at Springerlink.com
ABSTRACT
The role of retinal photocoagulation as a first
line therapy for various retinal pathologies has
decreased with the introduction of anti-vascular
endothelial growth factor therapy. However,
retinal laser therapy remains an important
treatment modality, especially with the emer-
gence of micropulse subthreshold treatment
and the integration of newer technology such as
augmented reality and semi-automated deliv-
ery. This review summarizes current evidence
for micropulse laser as a treatment modality and
discusses the role of new technology such as
augmented reality in the future of laser therapy.
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INTRODUCTION
Laser photocoagulation has been in use for the
last several decades to treat various retinal dis-
orders, including proliferative diabetic
retinopathy (PDR), diabetic macular edema
(DME), macular edema associated with retinal
vein occlusion (RVO), central serous chori-
oretinopathy (CSC) and choroidal neovascular-
ization (CNV). Its efficacy and safety have been
studied extensively in several landmark studies
published in the 1980s [1–5]. However, with the
advent of anti-vascular endothelial growth fac-
tor (VEGF) therapy and its success in the treat-
ment of various retinal pathologies, the
utilization of conventional thermal photoco-
agulation has declined.
Whether there is still a role for laser therapy
for these entities in the anti-VEGF era and if so,
to what capacity, are questions that are being
asked more frequently. In this paper we will
review the potential role of micropulse laser as
an adjunct and the evidence for its efficacy in
the treatment of common retinal pathologies.
In addition, we discuss recent innovations,
specifically augmented reality technology and
automated laser delivery capabilities and their
role in the future of laser retinal therapy.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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Conventional laser therapy is thought to induce
its therapeutic effect by targeting metabolically
active photoreceptors, thereby decreasing the
hypoxic drive and VEGF production. In terms of
focal laser for the treatment of macular edema,
direct laser photocoagulation of microa-
neurysms is thought to be the mechanism of
action [6, 7]. However, there is increasing evi-
dence that the retinal pigment epithelium
(RPE), after heat stimulation by a nearby laser
burn, is ultimately responsible for modulating
the exudative response [8]. Furthermore, sub-
threshold laser therapy, a term used to describe
the deliverance of laser energy below the
threshold of causing permanent tissue destruc-
tion, has been shown to alter the metabolic
activity and gene expression of the RPE, result-
ing in the release of growth factors and cytoki-
nes that regulate angiogenesis and vascular
leakage [9–11]. These changes in protein
expression of the RPE by subthreshold laser
have also been demonstrated on a histologic
level [12].
Laser parameters such as wavelength, power,
spot size and pulse duration, can be altered in
order to decrease the amount of thermal energy
delivered to limit permanent tissue damage.
Micropulse laser has emerged as the main
modality to achieve subthreshold treatment
where a visible laser burn is not detectable, even
with fluorescein angiography or autofluores-
cence imaging. Micropulse laser achieves this
subthreshold application by decreasing the
‘‘duty cycle’’ of the laser. Instead of one single
continuous pulse, the laser energy is divided
into numerous short repetitive pulses typically
from 100 to 300 ls with 1700–1900 ls in
between each pulse. This effectively decreases
the ‘‘duty cycle’’ of the laser to as low as
5%–10% of the conventional laser. By having
extended periods of rest in between each laser
micropulse, the retinal tissue is able to disperse
the accumulated heat to avoid the threshold of
apoptosis and cell death. Micropulse power as
low as 10% of the threshold power has been
demonstrated to result in localized changes in
the RPE while sparing the neurosensory retina
on light and electron microscopy [13]. There are
currently several commercially available micro-
pulse laser systems: Quantel Medical (Cedex,
France) 577 nm; IRIDEX (Mountain View, CA)
532 and 577 nm; and OD-OS (Berlin, Germany)
577 nm. There is emerging evidence that
micropulse laser may be as effective as conven-
tional laser photocoagulation in the treatment
of various retinal pathologies, the most perti-
nent of which will be reviewed.
Diabetic Macular Edema
Micropulse laser has been shown in several
randomized control trials to be as or more
effective than conventional focal laser photo-
coagulation in the treatment of DME [14–16]. In
these studies, visual acuity was found to be
either equivalent or superior in the micropulse
laser group when compared with the conven-
tional focal laser group at 1 year. A study with
long-term follow-up demonstrated sustained
visual and anatomic improvement at 3 years
[17]. In addition, several groups have shown
better preservation of electrophysical function
with micropulse laser as revealed by either
multifocal electroretinogram or microperimetry
[18, 19]. There have been no studies comparing
micropulse laser to anti-VEGF, which is cur-
rently the treatment of choice. However, focal
laser may have an important role in DME
refractive to anti-VEGF or non-fovea-involving
DME, especially in light of the effectiveness of
subthreshold tissue-sparing laser therapy.
Macular Edema Secondary to Retinal Vein
Occlusion
Currently, studies of micropulse laser for the
treatment of macular edema due to RVOs have
been very limited. Parodi et al. published the
only randomized control trial comparing the
effect of micropulse laser in this entity with
conventional threshold laser therapy and found
no difference between the two groups in terms
of vision and resolution of edema at 2 years
[20]. The same group of investigators recently
compared micropulse laser to intravitreal
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bevacizumab for the treatment of macular
edema secondary to RVO recurring after con-
ventional laser therapy and found bevacizumab
to be superior in both visual and anatomical
outcomes at 1-year follow-up [21]. Currently,
the role of micropulse laser in this group of
patients appears to be limited.
Central Serous Chorioretinopathy
Subretinal fluid accumulation in CSC is thought
to be secondary to a combination of choroidal
hyperpermeability and RPE dysfunction. The
majority of cases resolve spontaneously but
treatment of recurrent and chronic disease can
be challenging. Existing treatment modalities
include conventional laser photocoagulation
and photodynamic therapy (PDT). Secondary
choroidal neovascularization and subretinal
scarring can result from chronic untreated CSC
or from conventional laser therapy. Micropulse
laser has been shown in several studies to result
in resolution of subretinal fluid [22–25]. How-
ever, these studies either lacked a control group
or were limited in the size of the study.
Proliferative Diabetic Retinopathy
Currently evidence for the efficacy of micro-
pulse laser for the treatment of proliferative
diabetic retinopathy is limited. There is one
published report on subthreshold micropulse
laser as an alternative to conventional panreti-
nal photocoagulation to date [26]. In the study
ninety-nine eyes were treated with micropulse
laser, and, at 1-year follow up, 12.5% developed
vitreous hemorrhage and 14.6% underwent
vitrectomy. The authors concluded that this
was similar to previously published reports on
outcomes with conventional panretinal photo-
coagulation. However, the analysis included
thirty-five eyes with severe non-proliferative
diabetic retinopathy. Furthermore, the study
was limited by an uncontrolled design, rela-
tively small sample size, and short follow- up.
As opposed to entities like DME and CSC
where the pathophysiology involves RPE dys-
function, for which micropulse laser may be
able to stimulate resorption of fluid even with
subthreshold energies, proliferative diabetic
retinopathy may involve a different patho-
physiology. The major hypothesis in prolifera-
tive diabetic retinopathy involves angiogenic
stimulus from ischemic retina, the destruction
of which leads to decreased angiogenic stimulus
and improved oxygenation of the remaining
non-ischemic retina [27]. Further studies
including randomized control trials of micro-
pulse laser in proliferative diabetic retinopathy
are needed.
As anti-VEGF therapy become the first-line
therapy in various retinal diseases, the routine
use of conventional macular laser has declined
significantly. However, in difficult cases that are
refractive to anti-VEGF therapy or in cases with
significant treatment burden from continuous
injections, focal laser is still an important
treatment modality. Subthreshold micropulse
laser is a less invasive alternative to conven-
tional laser photocoagulation that has been
shown to be as or more effective in the treat-
ment of DME without causing permanent tissue
damage [14–16]. Its role in the treatment of
other retinal diseases is yet to be determined.
Future randomized control trials are required to
better understand how this modality can be
applied with more clearly defined clinical
guidelines.
AUGMENTED REALITY
Augmented reality is the integration of com-
puter-generated information with the user’s
environment in real time. It uses the existing
environment and overlays useful information
on top of it. An everyday example is the
ten-yard line that is ubiquitous when watching
an American football match on television. The
yellow line, which is not physically present on
the field and is only seen by the television
audience, marks the location of the first down
marker. Augmented reality has many useful
applications in medicine. Examples range from
the projection of a patient’s vein over the skin
in preparation for obtaining intravenous access
to the overlay of previously acquired 3-D images
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onto the surgical field to label important
anatomical landmarks.
Navigated laser therapy is an example of
augmented reality in the field of retinal laser
therapy. It utilizes an eye-tracking laser delivery
system with the ability to overlay infrared, flu-
orescein angiography, and optical coherence
tomography images onto the real time-fundus
image. Registered image overlays allow the sur-
geon to map and target precise treatment areas
while the eye-tracking system compensates for
patient movement. In addition, preset grid
patterns with equidistant spacing can be deliv-
ered semi-automatically to the planned treat-
ment area with precision. Navigated laser
therapy has been shown to significantly
increase the accuracy of laser delivery with
greater than 95% of laser spots delivered within
100 microns of the desired target [28, 29]. This
is particularly important when targeting
microaneurysms in the treatment of DME.
Accurate laser delivery contributes to the effi-
cacy of navigated laser delivery [30, 31]. In
addition, two studies have demonstrated a
reduced treatment burden with anti-VEGF
therapy when combined with navigated laser
therapy [32, 33]. Furthermore, subthreshold
micropulse mode is integrated into the com-
mercially available navigated laser platform
with documentation of treatment spots. This is
critical when planning for repeat treatments
because previously treated areas are invisible
with micropulse laser.
CONCLUSION
The role of retinal photocoagulation as a first
line therapy for various retinal pathologies has
largely been replaced with anti-VEGF since its
introduction. However, despite the emergence
of anti-VEGF, retinal laser therapy still has an
important role in the treatment of many dis-
eases and is a useful modality in a retina spe-
cialist’s armamentarium. Recent advances such
as micropulse subthreshold laser, which has
been demonstrated to be especially effective in
DME, will be utilized more widely as results
from randomized controlled clinical trials are
made available. Furthermore, the future of
retinal laser therapy will include wider adoption
of augmented reality such as navigated laser to
assist surgeons in more accurate treatments
with semi-automated delivery.
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